PD-1 / PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Se han encontrado 183 productos para "PD-1 / PD-L1".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Pureza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:145.14 kDa (Predicted)Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Pureza:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Forma y color:LiquidPeso molecular:143.78 kDa (Predicted)Zimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Pureza:95%Forma y color:Transparent LiquidPeso molecular:146.54 kDa (Predicted)AUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFórmula:C144H230N40O50Pureza:95.07% - 99.29%Forma y color:White SolidPeso molecular:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Pureza:97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:146.03 kDa (Predicted)BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFórmula:C35H35ClN2O7Pureza:97.36%Forma y color:SolidPeso molecular:631.115Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Pureza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:145.72 kDa (Predicted)Dostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Pureza:>95%Forma y color:Transparent LiquidPeso molecular:144.18 kDa (Predicted)Tislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Pureza:95.07%Forma y color:Transparent LiquidPeso molecular:145 kDa (Predicted)Ezabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Pureza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:145.21 kDa (Predicted)Spartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Pureza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Forma y color:Transparent LiquidPeso molecular:145.74 kDa (Predicted)Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPureza:98%Forma y color:SolidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Fórmula:C22H24N2O2Pureza:99.92%Forma y color:SolidPeso molecular:348.4382Eciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPureza:98%Forma y color:SolidIparomlimab
CAS:Iparomlimab serves as a functional therapeutic tool specifically designed to enable the precise detection and neutralization of the PD-1 protein which plays a pivotal role in the induction of peripheral tolerance and tumor immune evasion during strictly monitored laboratory observation periods and molecular investigations to evaluate the pharmacological potential of targeted checkpoint inhibition in specialized preclinical research environments to facilitate the study of cancer immunotherapies.Pureza:95%Forma y color:Transparent LiquidPeso molecular:146.70 kDa (Predicted)MS1-96
MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Forma y color:Odour SolidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Fórmula:C109H151F3N34O34S2Forma y color:SolidPeso molecular:2602.69HLX43
HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.Pureza:95% - 98.30% (SEC-HPLC)Peso molecular:153.06 kDa (Predicted)Human PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Fórmula:C110H152N26O32Forma y color:SolidPeso molecular:2350.576
